Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

@article{Jallad2005TreatmentOA,
  title={Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.},
  author={R S Jallad and Nina Rosa de Castro Musolino and Luiz Roberto Salgado and M D Bronstein},
  journal={Clinical endocrinology},
  year={2005},
  volume={63 2},
  pages={168-75}
}
OBJECTIVE Somatostatin analogues have become the mainstay of the medical treatment of acromegaly. The aim of our study was to evaluate the efficacy and tolerability of octreotide-LAR (OCT-LAR) treatment in acromegalic patients. DESIGN Prospective open trial. PATIENTS AND METHODS Eighty acromegalic patients (46 women; 18-80 years) were treated with OCT-LAR. Mean +/- SD duration of follow-up was 16.6 +/- 6.6 months (6-24 months). Twenty-eight patients received OCT-LAR as primary treatment… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Octreotide Long-Acting Release (LAR)

View 10 Excerpts
Highly Influenced

Acromegaly : Current Challenges and Future Directions in Latin America

Enrique Lopez Gavilanez, Noemi Bautista Litardo, +7 authors Angelo Caputi Zúñiga
2018
View 2 Excerpts

Similar Papers

Loading similar papers…